Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › China Phase II (obesity, non-diabetic)

China Phase II (obesity, non-diabetic)

HDM1005 · obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
HDM1005
Population
obesity
Phase
2
Participants
243
Duration
22 weeks

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
2.0 mgobesity china22243——−13.3 % vs −2.5 %
estimand not specified
———————press release
4.0 mgobesity china22243——−13.3 % vs −2.5 %
estimand not specified
———————press release

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (2)
  • 2.0 mg · weight_unsp · secondary
    2.0mg剂量组体重较基线降幅达13.31%,4.0mg组达13.28%,显著优于安慰剂组的2.46%
  • 4.0 mg · weight_unsp · secondary
    2.0mg剂量组体重较基线降幅达13.31%,4.0mg组达13.28%,显著优于安慰剂组的2.46%

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: China Phase II (obesity, non-diabetic). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/china-phase-ii/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.